Published in Arthritis Rheum on April 01, 2008
Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clin Immunol (2011) 1.39
A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol (2010) 0.90
Immunologic changes in frail older adults. Transl Med UniSa (2014) 0.87
Sarcoidosis and tuberculosis cytokine profiles: indistinguishable in bronchoalveolar lavage but different in blood. PLoS One (2012) 0.87
Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. Front Pharmacol (2014) 0.86
Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum (2010) 0.80
Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs (2015) 0.77
Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol (2012) 0.77
A methodology for exploring biomarker--phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations. BMC Bioinformatics (2015) 0.76
The role of the acquired immune response in systemic sclerosis. Semin Immunopathol (2015) 0.75
Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res Ther (2016) 0.75
Humanized mouse model for assessing the human immune response to xenogeneic and allogeneic decellularized biomaterials. Biomaterials (2017) 0.75
Multiparameter flow cytometry for discovery of disease mechanisms in rheumatic diseases. Arthritis Rheum (2013) 0.75
Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med (1999) 29.97
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis (1991) 13.67
Criteria for the classification of early systemic sclerosis. J Rheumatol (2001) 5.39
Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest (2007) 5.19
Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol (1995) 4.11
The Th1/Th2 paradigm. Immunol Today (1997) 3.96
Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol (2002) 3.07
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Immunopathology of schistosomiasis. Immunol Cell Biol (2006) 2.74
Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum (1992) 2.38
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum (1999) 2.22
Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol (1987) 2.00
Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol (1997) 1.95
Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med (2005) 1.93
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol (1992) 1.81
Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res (1996) 1.77
The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis (1987) 1.55
Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol (2005) 1.47
Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol (1997) 1.43
Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol (2002) 1.36
Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol (2003) 1.31
The immunobiology of Th1 polarization in high-pathology schistosomiasis. Immunol Rev (2004) 1.27
Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology (1990) 1.13
Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum (2003) 1.10
Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol (1997) 1.09
Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest (1983) 1.03
Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol (2002) 1.01
Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor beta. Arthritis Rheum (2006) 1.01
GATA3 up-regulation associated with surface expression of CD294/CRTH2: a unique feature of human Th cells. Blood (2007) 0.98
Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol (2001) 0.98
Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol (1996) 0.95
Differential regulation of glycosaminoglycan, fibronectin, and collagenase production in cultured human dermal fibroblasts by interferon-alpha, -beta, and -gamma. Arch Dermatol Res (1989) 0.93
Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol (1997) 0.92
A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol (1997) 0.91
Granzyme B induces endothelial cell apoptosis and contributes to the development of transplant vascular disease. Am J Transplant (2005) 0.85
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum (2011) 2.99
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med (2005) 2.82
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med (2013) 2.51
Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med (2013) 2.51
Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2013) 2.46
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med (2011) 2.19
'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought. Rheumatology (Oxford) (2011) 1.92
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol Chem (2002) 1.88
Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature (2013) 1.86
Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol (2010) 1.85
Randomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research Centers. J Allergy Clin Immunol (2009) 1.81
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol (2011) 1.80
Differential mucosal IL-17 expression in two gliadin-induced disorders: gluten sensitivity and the autoimmune enteropathy celiac disease. Int Arch Allergy Immunol (2009) 1.78
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med (2002) 1.78
Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol (2010) 1.73
Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol (2006) 1.73
Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum (2005) 1.67
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol (2005) 1.66
Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am (2003) 1.65
Are overweight and obese adults with arthritis being advised to lose weight? J Clin Rheumatol (2007) 1.63
Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum (2006) 1.57
Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA stabilization: involvement of the RNA-binding protein HuR. J Immunol (2003) 1.57
Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum (2010) 1.54
Apoptotic cell blebs: repositories of autoantigens and contributors to immune context. Arthritis Rheum (2009) 1.53
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.53
Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum (2002) 1.53
Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum (2008) 1.48
Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum (2008) 1.45
Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann Rheum Dis (2011) 1.45
Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.44
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum (2005) 1.42
Retracted Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A (2002) 1.41
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum (2009) 1.40
Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation. Arthritis Rheum (2010) 1.39
Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol (2008) 1.32
Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol (2003) 1.31
Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum (2009) 1.31
Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice. PLoS Med (2005) 1.28
Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum (2008) 1.28
Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum (2013) 1.27
Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res (2008) 1.27
Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol (2011) 1.26
Apoptosis and autoimmunity. Curr Opin Immunol (2005) 1.25
Yoga for arthritis: a scoping review. Rheum Dis Clin North Am (2010) 1.25
Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care (2003) 1.24
Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum (2010) 1.23
Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol (2002) 1.23
Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum (2013) 1.23
Body image dissatisfaction among women with scleroderma: extent and relationship to psychosocial function. Health Psychol (2003) 1.21
Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail (2013) 1.21
Relationship between body weight gain and significant knee, hip, and back pain in older Americans. Obes Res (2003) 1.20
Environmental tobacco smoke exposure and nocturnal symptoms among inner-city children with asthma. J Allergy Clin Immunol (2002) 1.19
Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J (2006) 1.19
Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology (2010) 1.18
The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest (2007) 1.18
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum (2007) 1.17
Impact of interview mode on accuracy of child and parent report of adherence with asthma-controller medication. Pediatrics (2007) 1.17
Do asthma medication beliefs mediate the relationship between minority status and adherence to therapy? J Asthma (2008) 1.14
Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol (2003) 1.11
Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol (2003) 1.11
Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A (2012) 1.10
Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol (2009) 1.10
Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum (2003) 1.10
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant (2005) 1.09
Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am (2004) 1.09
Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) (2008) 1.09
Granzyme H destroys the function of critical adenoviral proteins required for viral DNA replication and granzyme B inhibition. EMBO J (2007) 1.09
The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative. Health Qual Life Outcomes (2013) 1.08
Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway. J Biol Chem (2006) 1.08
Posttranscriptional regulation of IL-13 in T cells: role of the RNA-binding protein HuR. J Allergy Clin Immunol (2008) 1.08
Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol (2002) 1.08
The impact of pain and symptoms of depression in scleroderma. Pain (2002) 1.08
Caspase-resistant Golgin-160 disrupts apoptosis induced by secretory pathway stress and ligation of death receptors. Mol Biol Cell (2005) 1.07
How common is hip pain among older adults? Results from the Third National Health and Nutrition Examination Survey. J Fam Pract (2002) 1.07
Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum (2008) 1.06
Inhibition of cytokine gene transcription by the human recombinant histamine-releasing factor in human T lymphocytes. J Immunol (2003) 1.05
Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. J Rheumatol (2011) 1.05
Apoptosis in systemic lupus erythematosus. Curr Opin Rheumatol (2003) 1.05
T-lymphocytes expressing CC chemokine receptor-5 are increased in frail older adults. J Am Geriatr Soc (2008) 1.05
Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response. Proc Natl Acad Sci U S A (2003) 1.03
Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum (2006) 1.03
A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore) (2012) 1.03
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum (2009) 1.03
Are health care professionals advising adults with arthritis to become more physically active? Arthritis Rheum (2005) 1.03
Age and risk of pulmonary arterial hypertension in scleroderma. Chest (2003) 1.02
Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr Opin Rheumatol (2003) 1.01
Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. J Rheumatol (2014) 1.00
Expression of genes for B7-H3 and other T cell ligands by nasal epithelial cells during differentiation and activation. Am J Physiol Lung Cell Mol Physiol (2004) 1.00
The ILAR-East Africa initiative: current needs and progress in the globalization of rheumatology. Clin Rheumatol (2010) 0.99
IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis (2012) 0.98
GATA3 up-regulation associated with surface expression of CD294/CRTH2: a unique feature of human Th cells. Blood (2007) 0.98
Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells. Am J Physiol Lung Cell Mol Physiol (2005) 0.98
Sexual dimorphism in immune response genes as a function of puberty. BMC Immunol (2006) 0.98